New trial aims to boost survival in kids with rare lymphoma

NCT ID NCT05681260

First seen Mar 22, 2026 · Last updated Jun 11, 2026 · Updated 14 times

Summary

This study compares two different ways of giving methotrexate (a chemotherapy drug) to children and teens newly diagnosed with T-cell lymphoblastic lymphoma, a rare cancer of the immune system. About 200 participants will be randomly assigned to one of two treatment plans to see which leads to better event-free survival. The goal is to find the most effective approach with fewer side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T CELL LYMPHOBLASTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Children's Medical Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200127, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • West China Second University Hospital

    NOT_YET_RECRUITING

    Chengdu, China

    Contact

Conditions

Explore the condition pages connected to this study.